schliessen

Filtern

 

Bibliotheken

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects

Background Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examinati... Full description

Journal Title: The American heart journal 2011, Vol.161 (4), p.719-725
Main Author: Muntner, Paul, PhD
Other Authors: Mann, Devin, MD , Wildman, Rachel P, PhD , Shimbo, Daichi, MD , Fuster, Valentin, MD , Woodward, Mark, PhD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Age
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-8703
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3093765
title: Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
format: Article
creator:
  • Muntner, Paul, PhD
  • Mann, Devin, MD
  • Wildman, Rachel P, PhD
  • Shimbo, Daichi, MD
  • Fuster, Valentin, MD
  • Woodward, Mark, PhD
subjects:
  • Abridged Index Medicus
  • Adults
  • Age
  • Aspirin
  • Atherosclerosis (general aspects, experimental research)
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Blood pressure
  • Cardiology. Vascular system
  • Cardiovascular
  • Cardiovascular disease
  • Cardiovascular diseases
  • Cardiovascular Diseases - drug therapy
  • Cardiovascular Diseases - epidemiology
  • Cardiovascular Diseases - prevention & control
  • Cholesterol
  • Clinical trials
  • Complications and side effects
  • Diabetes
  • Drug Combinations
  • Drug therapy
  • Female
  • Heart attacks
  • Humans
  • Incidence
  • Male
  • Medical sciences
  • Meta-analysis
  • Middle Aged
  • Older people
  • Population
  • Risk Factors
  • Surveys and Questionnaires
ispartof: The American heart journal, 2011, Vol.161 (4), p.719-725
description: Background Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.420933
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3093765
sourceformatXML
sourcesystemPC
galeidA253635972
sourcerecordidA253635972
originalsourceidFETCH-LOGICAL-1635t-3ac79ec185fbdc178827ac5b3f2847dcafb64c5fa655344a0593141b8ce115f93
addsrcrecordideNp9k1tr2zAYhs3YWLNuP2A3QzDGbppMsmTL7qBQyk7QsUHXa6HokMpVpFSyA_n3-7xkzRpG8YUs6Xm_g_SqKF4TPCOY1B-6mbzpZiUe5-UMk_ZJMSG45dOaM_a0mGCMy2nDMT0qXuTcwbQum_p5cVQSxmnLyaS4-5liZ1RvNHLLlVQ9ihatot-snPdoyAbJZQwLdH2FpB58n0_Rd6Odkr2LYdw_QUom7eJaZjV4mVBy-RYlowc1IidIBo2y0wYZayFRflk8s9Jn82o3HhfXnz_9uvg6vfzx5dvF-eWU1LTqp1Qq3hpFmsrOtSK8aUouVTWntmwY10raec1UZWVdVZQxiauWEkbmjTKEVLalx8XZNu5qmC-NVib0SXqxSm4p00ZE6cTDneBuxCKuBcUt5XUFAd7vAqR4N5jci6XLyngvg4lDFk1NSsyhQCDfHpBdHFKA7gSpWMOAYWRPLaQ3wgUbIa0aY4rzsqLQdctLoGb_oeDTZulUDMY6WH8gIFuBSjHnZOx9iwSL0SaiE2ATMdpEkFKATUDz5t-zuVf89QUA73YAXKv0NsmgXN5zDDcVYRQ4fpBcuf6PN6Bq5x8t4eNWacADa2eSyMqZoMBcCWwidHSPqs8O1Mq7ALb0t2Zj8v74RQaBuBpfwvgQCIE_3BD6G_2NAPY
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1548418541
display
typearticle
titleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
sourceAlma/SFX Local Collection
creatorMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
creatorcontribMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
descriptionBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2010.12.019
3PMID: 21473971
4CODEN: AHJOA2
languageeng
publisherNew York, NY: Elsevier Inc
subjectAbridged Index Medicus ; Adults ; Age ; Aspirin ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Cholesterol ; Clinical trials ; Complications and side effects ; Diabetes ; Drug Combinations ; Drug therapy ; Female ; Heart attacks ; Humans ; Incidence ; Male ; Medical sciences ; Meta-analysis ; Middle Aged ; Older people ; Population ; Risk Factors ; Surveys and Questionnaires
ispartofThe American heart journal, 2011, Vol.161 (4), p.719-725
rights
0Mosby, Inc.
12011 Mosby, Inc.
22015 INIST-CNRS
3Copyright © 2011 Mosby, Inc. All rights reserved.
4COPYRIGHT 2011 Elsevier B.V.
5Copyright Elsevier Limited Apr 2011
62011 Mosby, Inc. All rights reserved. 2011
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1635t-3ac79ec185fbdc178827ac5b3f2847dcafb64c5fa655344a0593141b8ce115f93
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24085143$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21473971$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
title
0Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
1The American heart journal
addtitleAm Heart J
descriptionBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
subject
0Abridged Index Medicus
1Adults
2Age
3Aspirin
4Atherosclerosis (general aspects, experimental research)
5Biological and medical sciences
6Blood and lymphatic vessels
7Blood pressure
8Cardiology. Vascular system
9Cardiovascular
10Cardiovascular disease
11Cardiovascular diseases
12Cardiovascular Diseases - drug therapy
13Cardiovascular Diseases - epidemiology
14Cardiovascular Diseases - prevention & control
15Cholesterol
16Clinical trials
17Complications and side effects
18Diabetes
19Drug Combinations
20Drug therapy
21Female
22Heart attacks
23Humans
24Incidence
25Male
26Medical sciences
27Meta-analysis
28Middle Aged
29Older people
30Population
31Risk Factors
32Surveys and Questionnaires
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2011
recordtypearticle
recordideNp9k1tr2zAYhs3YWLNuP2A3QzDGbppMsmTL7qBQyk7QsUHXa6HokMpVpFSyA_n3-7xkzRpG8YUs6Xm_g_SqKF4TPCOY1B-6mbzpZiUe5-UMk_ZJMSG45dOaM_a0mGCMy2nDMT0qXuTcwbQum_p5cVQSxmnLyaS4-5liZ1RvNHLLlVQ9ihatot-snPdoyAbJZQwLdH2FpB58n0_Rd6Odkr2LYdw_QUom7eJaZjV4mVBy-RYlowc1IidIBo2y0wYZayFRflk8s9Jn82o3HhfXnz_9uvg6vfzx5dvF-eWU1LTqp1Qq3hpFmsrOtSK8aUouVTWntmwY10raec1UZWVdVZQxiauWEkbmjTKEVLalx8XZNu5qmC-NVib0SXqxSm4p00ZE6cTDneBuxCKuBcUt5XUFAd7vAqR4N5jci6XLyngvg4lDFk1NSsyhQCDfHpBdHFKA7gSpWMOAYWRPLaQ3wgUbIa0aY4rzsqLQdctLoGb_oeDTZulUDMY6WH8gIFuBSjHnZOx9iwSL0SaiE2ATMdpEkFKATUDz5t-zuVf89QUA73YAXKv0NsmgXN5zDDcVYRQ4fpBcuf6PN6Bq5x8t4eNWacADa2eSyMqZoMBcCWwidHSPqs8O1Mq7ALb0t2Zj8v74RQaBuBpfwvgQCIE_3BD6G_2NAPY
startdate2011
enddate2011
creator
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
general
0Elsevier Inc
1Mosby
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117QO
127RV
137TS
147X7
157XB
1688C
1788E
188AO
198C1
208FD
218FI
228FJ
238FK
248G5
25ABUWG
26AN0
27AZQEC
28BENPR
29DWQXO
30FR3
31FYUFA
32GHDGH
33GNUQQ
34GUQSH
35K9.
36KB0
37M0S
38M0T
39M1P
40M2O
41MBDVC
42NAPCQ
43P64
44PADUT
45PQEST
46PQQKQ
47PQUKI
48PRINS
49Q9U
507X8
515PM
sort
creationdate2011
titleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
authorMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1635t-3ac79ec185fbdc178827ac5b3f2847dcafb64c5fa655344a0593141b8ce115f93
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Abridged Index Medicus
1Adults
2Age
3Aspirin
4Atherosclerosis (general aspects, experimental research)
5Biological and medical sciences
6Blood and lymphatic vessels
7Blood pressure
8Cardiology. Vascular system
9Cardiovascular
10Cardiovascular disease
11Cardiovascular diseases
12Cardiovascular Diseases - drug therapy
13Cardiovascular Diseases - epidemiology
14Cardiovascular Diseases - prevention & control
15Cholesterol
16Clinical trials
17Complications and side effects
18Diabetes
19Drug Combinations
20Drug therapy
21Female
22Heart attacks
23Humans
24Incidence
25Male
26Medical sciences
27Meta-analysis
28Middle Aged
29Older people
30Population
31Risk Factors
32Surveys and Questionnaires
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Biotechnology Research Abstracts
11Nursing & Allied Health Database
12Physical Education Index
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Healthcare Administration Database (Alumni)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Technology Research Database
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23Research Library (Alumni Edition)
24ProQuest Central (Alumni Edition)
25British Nursing Database
26ProQuest Central Essentials
27ProQuest Central
28ProQuest Central Korea
29Engineering Research Database
30Health Research Premium Collection
31Health Research Premium Collection (Alumni)
32ProQuest Central Student
33Research Library Prep
34ProQuest Health & Medical Complete (Alumni)
35Nursing & Allied Health Database (Alumni Edition)
36Health & Medical Collection (Alumni Edition)
37Healthcare Administration Database
38Medical Database
39Research Library
40Research Library (Corporate)
41Nursing & Allied Health Premium
42Biotechnology and BioEngineering Abstracts
43Research Library China
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central China
48ProQuest Central Basic
49MEDLINE - Academic
50PubMed Central (Full Participant titles)
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
formatjournal
genrearticle
ristypeJOUR
atitleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
jtitleThe American heart journal
addtitleAm Heart J
date2011
risdate2011
volume161
issue4
spage719
epage725
pages719-725
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
copNew York, NY
pubElsevier Inc
pmid21473971
doi10.1016/j.ahj.2010.12.019
oafree_for_read